Gut health

The review reported improvements in fatigue or symptoms after exertion with some gut-focused interventions, and fatigue improvement with brain stimulation combined with exercise. Several other stimulation approaches showed limited efficacy. A separate electroacupuncture case also improved, but a single case cannot establish treatment effects. The abstract leaves both benefit sizes and the proposed brain–gut mechanisms uncertain.

Keep in mind: The abstract supplies no numerical treatment effects or trial comparator details. The case cannot establish causation, and the diverse interventions do not support a blanket effectiveness claim for treatments targeting brain–gut pathways.

The study identified a group of gut bacteria consistently associated with healthy status across diseases and countries. This makes it a candidate marker for further study. The analysis does not show that introducing these bacteria would improve health, and its predictions about microbial functions do not demonstrate nutritional benefits for people.

Keep in mind: This abstract-based account describes associations and predicted functions. The abstract does not report a human intervention, clinical benefits from changing these bacteria, or the length of observations over time.

After daily intake of the tested probiotic strain, the human trial reported increases in an antimicrobial peptide and several antibodies. Gut microbial features also changed, while a diversity measure showed no statistically significant change. These are laboratory outcomes; the abstract does not report whether participants had fewer infections, felt better, or experienced other clinical benefits.

Keep in mind: The comparator and reference for the percentage changes are unclear. Human adverse-event results are not supplied, and laboratory or mouse findings do not establish safety across human populations. This account is based on the abstract.

The tested probiotic increased several immune markers compared with placebo. Uric acid and LDL cholesterol also decreased, but those comparisons were with participants' starting values. These findings describe laboratory measurements; the abstract does not report fewer infections or other clinical benefits. Its safety assessments also cannot establish safety for every user or duration.

Keep in mind: The trial was small and short. The abstract does not provide the size of the immune-marker differences, placebo comparisons for the metabolic changes, or clinical adverse-event rates.

Probiotics were associated with better scores on cognitive tests in this review, with the authors highlighting studies that enrolled people with cognitive impairment. However, the studies differed substantially, and the abstract does not establish how these test changes translate into everyday functioning. The findings leave the clinical relevance of supplementation uncertain.

Keep in mind: Substantial differences across studies and limited biomarker evidence reduce certainty. The abstract does not specify treatment durations or establish whether cognitive score changes were meaningful in daily life.

Across the included studies, insomnia was associated with lower gut microbial diversity and a different mix of bacteria. These patterns may help frame future research, but they do not establish a cause of insomnia. The abstract also does not demonstrate that changing gut microbes improves sleep or that microbial testing can reliably diagnose insomnia.

Keep in mind: The reported observed-species estimate and confidence interval are internally inconsistent, so its size and direction cannot be interpreted reliably. The observational designs also leave the direction of the insomnia–microbiota relationship unresolved.

Probiotic supplementation was associated with improved depressive symptoms in the combined analysis. The measured inflammatory biomarkers did not show statistically significant changes. Because the abstract provides no effect size, participant total or comparison details, it cannot show how large or clinically meaningful the symptom improvement was, or establish whether inflammation explains it.

Keep in mind: The abstract reports statistical significance without effect estimates or confidence intervals. It also omits study designs, probiotic formulations and treatment durations, preventing a clear assessment of practical relevance.

The review reported improvements in sleep quality and depressive symptoms among women with polycystic ovary syndrome receiving probiotic interventions compared with placebo. Some quality-of-life domains also improved. These findings concern questionnaire scores in this specific population; the limited and varied studies do not establish a dependable treatment effect for all women with PCOS.

Keep in mind: Few studies, modest samples and differing methods limit confidence. The abstract gives no effect sizes or treatment durations, and this abstract-based summary cannot establish whether reported score changes were large enough to matter to participants.

Among patients with advanced liver disease, lower total testosterone was associated with a greater risk of death from any cause or liver transplantation during follow-up. This suggests a possible role as a marker of prognosis. The observational evidence cannot show that low testosterone caused these outcomes or that testosterone treatment would prevent them.

Keep in mind: The abstract omits follow-up lengths, testosterone thresholds, and adjustment details. Observational associations cannot determine whether testosterone itself has a causal role in the outcomes.

Some included studies reported less fatigue with thiamine, vedolizumab, upadacitinib or modafinil, but the review judged the available evidence insufficient. Thiamine results varied across studies, and vitamin B12 had not demonstrated a benefit. The abstract does not establish a preferred treatment or show that higher thiamine doses work better in a direct comparison.

Keep in mind: The abstract provides no treatment effect sizes, confidence intervals, follow-up durations or comparator details. It also includes participants with irritable bowel syndrome, so the combined population is not exclusively people with inflammatory bowel disease.

The synbiotic reduced scan-measured visceral fat area compared with placebo, but the abstract does not say how large the difference was. Blood biochemistry, BMI and waist circumference showed no statistically significant changes. The findings concern this particular combined formulation and do not establish a broader metabolic benefit or apply to all probiotic products.

Keep in mind: The abstract omits the size of the visceral-fat difference and its confidence interval, so practical importance remains unclear. It also does not describe safety outcomes.

This review of existing meta-analyses found shorter hospital stays with probiotic or synbiotic supplementation in surgical patients. Neither approach showed a statistically significant change in postoperative mortality, and synbiotics showed no clear change in intensive care stay. The findings do not establish a survival benefit or identify which supplement strategy is better.

Keep in mind: Many included reviews were rated critically low in quality, and the abstract does not specify supplement formulations, timing or safety outcomes.

This review explores how altered gut microbes might connect obesity with breast cancer progression. It discusses inflammation, hormone metabolism and immune effects, along with microbiome treatments under investigation. The abstract offers no pooled treatment estimates and calls for causal research and clinical validation, so it cannot establish that changing gut microbes improves cancer outcomes.

Keep in mind: The abstract does not report study counts, individual trial results or a formal assessment of evidence quality, limiting what can be judged about the treatment claims.

People discussing bowel dysfunction after rectal cancer surgery described practical challenges alongside emotional strain. Food tracking, adapting expectations and learning from peers featured in their accounts. The analysis highlights needs and experiences among active app users, but it cannot establish that the app or any specific self-management strategy improved bowel function.

Keep in mind: The authors identify a small sample and selection bias. This abstract-based account cannot establish how well the themes represent survivors who did not participate in the app.

People with diabetic retinopathy had different gut microbial communities, but pooled diversity measures did not clearly distinguish them from people with diabetes without retinopathy or from healthy controls. The findings describe patterns associated with diabetic eye disease; they do not establish that changing gut microbes would prevent or treat it.

Keep in mind: Studies varied substantially, with demographic and methodological limitations. This abstract-based account cannot establish that microbial changes cause retinopathy or that proposed microbiome treatments improve eye outcomes.

Higher-fiber and vegetarian diets were associated with particular gut bacteria and more favorable metabolic markers during pregnancy. Dietary fat and protein associations also differed according to maternal health status. These results describe links among diet, microbes and metabolism; they do not establish that a dietary change prevents gestational diabetes or other pregnancy complications.

Keep in mind: The review combined observational and intervention studies, and its meta-analysis assessed correlations. The abstract does not provide clinical effect estimates showing whether microbial changes translated into fewer pregnancy complications.

The review describes modest symptom improvements when probiotics were studied as an additional treatment for diagnosed major depression. Results varied across patient settings and formulations, and the abstract does not provide a pooled symptom effect. The findings therefore do not establish a broadly effective product or show that probiotics can replace depression treatment.

Keep in mind: Differences between methods, participant dropout and selective reporting remained concerns despite mostly low risk-of-bias ratings. The abstract supplies no pooled symptom effect or long-term follow-up, limiting estimates of benefit size and persistence.

The review found lower overall IBS symptom severity scores with multistrain probiotics than with placebo. Results varied greatly across studies, and some outcomes showed no statistically significant improvement. This abstract-based summary therefore supports a possible symptom benefit while leaving uncertainty about its consistency, its practical size and which probiotic mixtures contributed.

Keep in mind: The abstract reports very high variation between studies but does not explain which factors accounted for it. It also omits treatment durations, strain combinations and whether the average score difference was clinically meaningful.

Human findings were mixed: oral butyrate had no measurable effect in healthy men, while a separate trial in people with ulcerative colitis reported lower depression and anxiety symptoms. Animal studies supplied most of the evidence. This abstract-based review does not establish butyrate as an effective treatment for people with depression.

Keep in mind: The human trials involved different populations and durations. The abstract omits their sample sizes, comparator details and effect estimates, so it cannot explain the differing results or establish broader clinical effectiveness.

The review reported lower pain scores with cyclobenzaprine and pregabalin, mixed dietary findings, and no statistically significant probiotic benefit over placebo. These findings concern people with both fibromyalgia and IBS. The abstract does not quantify benefits or harms, and a nonsignificant probiotic result does not establish that probiotics have no effect.

Keep in mind: Only a small trial set contributed to the pooled analysis. The abstract omits treatment durations, drug comparators and numerical benefit or harm estimates, limiting assessment of clinical importance and durability.

This review examines how vagus nerve stimulation may alter gut microbes and how microbial products may influence the nerve in return. The authors describe connected neural, immune and metabolic pathways. The abstract offers a framework for studying treatments for brain disorders, but provides no patient outcome estimates or evidence that a new treatment works.

Keep in mind: The abstract does not describe the search methods, included study populations, evidence quality or treatment effects. It therefore cannot establish how well the proposed mechanisms translate into clinical benefits.

This abstract-based review found good overall discrimination for models predicting pancreatitis after ERCP, a procedure used for pancreatic and biliary disorders. However, differences in methods, possible bias and limited external testing restrict confidence. These findings concern prediction performance; they do not establish that using the models improves patient outcomes or prevents pancreatitis.

Keep in mind: Only 3 studies tested models using external data. The abstract describes substantial methodological variation and potential bias, and it does not report a pooled measure of how closely predicted risks matched observed risks.

Bacillus supplementation was associated with increases in several measures of diversity within fish gut microbial communities, while no significant change was reported in diversity between communities. The analysis also reported shifts in bacterial composition. These are microbiome findings in fish; the abstract does not establish improved growth, fewer infections, or relevance to human supplementation.

Keep in mind: This abstract-based summary lacks fish species, sample sizes, comparison-group details, and treatment durations. Microbial composition and diversity are the reported endpoints, so the authors' favorable interpretation should not be treated as demonstrated health benefit.

Most interventions did not produce statistically significant changes in overall microbial diversity. The review did find associations between some supplements and particular bacterial groups, and probiotic intake was associated with lower body weight and body fat. Those observations do not establish that changing the microbiome caused weight loss or produced lasting metabolic improvements.

Keep in mind: Methods and outcomes varied widely, and the abstract does not provide pooled effect sizes. The authors called for standardized methods and reporting before confirmation through meta-analysis; a causal link to lasting benefits remains uncertain.